GKOS
Glaukos Corporation
Price as of Jul 20, 2026
GKOS earnings
Glaukos Corporation earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $-0.30 | $-0.18 | +40.0% | $151M | +9.9% |
| Feb 17, 2026 | $-0.22 | $-0.28 | -27.3% | $143M | +6.5% |
| Oct 29, 2025 | $-0.27 | $-0.16 | +40.7% | $134M | +3.2% |
| Jul 30, 2025 | $-0.26 | $-0.24 | +7.7% | $124M | +1.4% |
| Apr 30, 2025 | $-0.33 | $-0.22 | +33.3% | $107M | +3.8% |
| Feb 20, 2025 | $-0.38 | $-0.40 | -5.3% | $105M | +4.5% |
| Jul 31, 2024 | $-0.52 | $-0.52 | +0.0% | $96M | +7.6% |
| May 1, 2024 | $-0.58 | $-0.70 | -20.7% | $86M | +7.6% |
| Feb 21, 2024 | $-0.56 | $-0.63 | -12.5% | $82M | +5.6% |
| Nov 1, 2023 | $-0.56 | $-0.50 | +10.7% | $78M | +3.7% |
| Aug 2, 2023 | $-0.57 | $-0.55 | +3.5% | $80M | +7.6% |
| May 3, 2023 | $-0.61 | $-0.59 | +3.3% | $74M | +9.1% |
Earnings call summary
Q1 FY2026 · April 29, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Record first quarter consolidated net sales. • Raised full year 2026 net sales guidance to 620 - 635 million. • Strong execution across global commercial and development priorities. • U.S. glaucoma franchise driven by IDOS-TR growth. • International glaucoma franchise scaled infrastructure. • Epioxa launched, redefining go-to-market for keratoconus. • Advanced clinical pipeline across novel therapeutic platforms.
Guidance
• Raised full year 2026 net sales guidance to 620 - 635 million from 600 - 620 million previously. • U.S. glaucoma franchise expected to have low 30% type growth for full year. • International glaucoma franchise expected to have low double digit growth with single digit growth in remaining quarters. • Corneal health franchise expected to have high single-digit growth for the entire year with puts and takes in individual quarters.
Segment performance
Consolidated net sales were $150.6 million, up 41% on a reported basis and 39% on a constant currency basis. U.S. glaucoma franchise: record net sales of $93.5 million, up 58% y-o-y, with IDOS-TR generating ~$54M. International glaucoma franchise: record net sales of $35.8 million, up 23% on a reported basis and 16% on a constant currency basis. Corneal health franchise: net sales of 21.3 million, up 15%, including Trexa and early Epioxa net sales of 17.7 million. IDOS-TR has 22 peer-reviewed publications and active Phase IV studies. Epioxa is commercially available, with efforts to expand site of care network and secure payer access.
Risks & headwinds
• Risks related to forward-looking statements, including uncertainties in operations, business environment, regulatory strategies, reimbursement, etc. • Potential LCD risks for IDOS, although current view is it's premature at this stage of clinical adoption curve. • Risks associated with market access hurdles for Epioxa such as payer adoption headwinds and hurdles.
Analyst Q&A
Q: Talk about early findings on Epioxa claims and prior auth processes, and demand from early utilization.
A: Joe mentioned progress with site of care network and payer pathways, encouraged by leading indicators in patient flow.
Q: Drivers of IDOS strength and Noridian, Novitas vs remaining MACs.
A: Joe said broad-based drivers, with earlier adopting MACs' contribution changing and broader patient flow funnel.
Q: Modeling help on updated guidance, drivers of U.S. glaucoma, corneal health.
A: Joe discussed growth drivers for each franchise, including international glaucoma currency effects, corneal health transition dynamics, and U.S. glaucoma growth expectations.
Q: Engagement with MAC since CAC meeting, LCD likelihood, Phase 4 studies.
A: Joe talked about MAC engagement, LCD view as premature, and details on Phase 4 studies.
Q: Existing body of evidence vs Phase 4 study for IDOS.
A: Joe and Tom discussed trends in IDOS usage, mix of standalone and combinatorial procedures, and studies for payers.
Q: Operating expense guidance and profitability.
A: Alex discussed operating expenses, reinvestment, and path to profitability.
Q: Core U.S. glaucoma business outlook.
A: Alan was told of stabilization but caution in re-rating view.
Q: Corneal health site of care network progress.
A: Alan was told of acceleration and progress towards 95% target.
Q: Epioxa market development efforts.
A: Joe discussed site of care, payer access, and initial launch machinery.
Q: IDOS re-implantation approval and interplay with labels.
A: Joe said seen successful re-administration, payer policy updates, and progress.
Q: Provider base transition for Epioxa and spend direction.
A: Joe said provider base to be in hundreds, spend in market access machinery.
Q: IDOS surgeon cohort utilization.
A: Joe said ongoing growth in utilization, with readministration becoming more material.
Q: Commercial payer progress for IDOS.
A: Joe said 99% patients have access pathways, 50% in plans with specific policies.
Q: Specialty pharmacy channel for Epioxa.
A: David was told early days of adjudicating claims, encouraged by Orsini's work.
Q: Gross margin expectations.
A: Alex said 84% margin in Q1, expecting 84% - 86% for the year.
Q: Epioxa buy and bill options and iDose Trio timeline.
A: Joe talked about buy and bill options, and iDose Trio timeline of filing by end 2026 and approval in Q4 2027.
Q: Physician pushback on Epioxa price.
A: Joe said pushback exists but not as material as initial launch.
Q: Epioxa Portrexa sunset and international expansion.
A: Joe said Portrexa to sunset by end 3Q, international expansion selective.
Q: True TAM for keratoconus and diagnostic pathway for Epioxa.
A: Joe discussed TAM estimates and investments in awareness and detection for Epioxa
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-07-29.